Genfit SA (GNFT) has released an update.
Genfit SA, a leader in liver disease research, has expanded its R&D portfolio, focusing on Acute-on-Chronic Liver Failure (ACLF) and other serious liver diseases. The company has successfully received FDA accelerated approval for Iqirvo®/elafibranor for Primary Biliary Cholangitis (PBC) and continues to advance its diagnostic and therapeutic programs. Genfit, headquartered in Lille, France, operates globally with key offices in Switzerland and the USA, and is publicly traded on Nasdaq and Euronext.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
